Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck ...
As more cell, gene and immunotherapy applications emerge for lentiviral vectors, demand for their production continues to rise. With its move last week into a larger manufacturing facility, CDMO ...
Lentiviral vectors pseudotyped with G glycoprotein from vesicular stomatitis virus (VSV-G) and baculovirus gp64 are inactivated by human complement. The extent of vector inactivation in serum from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback